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Summary A major problem in the chemotherapy of colorectal cancers is their resistance to most cytotoxic
drugs which may be due to insufficient cellular transport. Drugs conjugated to monoclonal antibodies
recognising tumour antigens may overcome these difficulties by providing access of active agents to the
tumour cells. The anti-tumour monoclonal antibody shown to localise in patients with colorectal cancer,
791T/36, has been investigated as a potential targeting antibody.
Eight cell lines were established from surgically resected material and were shown to bind 791T/36
antibody. They were screened for their sensitivity to methotrexate, 5-fluorouracil and daunomycin. Although
5-fluorouracil is the drug of choice for chemotherapy of colorectal cancer it was the most cytotoxic drug in
only 2 of the 8 cell lines. Only the 4 cell lines which were resistant to methotrexate showed less cytotoxicity
with methotrexate than 5-fluorouracil. The cell lines which were resistant to methotrexate were more sensitive
to 791T/36-methotrexate conjugates. Daunomycin was the most cytotoxic drug in 4 of the 8 cell lines.
However, a similar cytotoxicity was observed for free drug and 791T/36 daunomycin in the two lines tested.
Selective monoclonal antibody drug conjugates may offer a solution to treatment of tumours which are
resistant to classical chemotherapeutic agents. This is the first report to show that newly established cell lines
that are resistant to classical chemotherapeutic agents are rendered sensitive when the drug enters the cell as a
drug monoclonal antibody carrier.
Colorectal carcinoma is one of the most common solid
tumours in humans and is relatively resistant to all forms of
currently available chemotherapy. Several groups have
shown that antitumour antibodies can localise in colorectal
cancer (Mach et al., 1980; Chatal et al., 1982) and it has
been proposed that they may be used to direct therapeutic
drugs to tumour cells. Monoclonal antibody, 791T/36, raised
against osteogenic sarcoma cells (Embleton et al., 1981)
binds to colorectal cancer cell (Durrant et al., 1986a) and
has been shown to localise in colorectal cancer (Farrands et
al., 1982; Armitage et al., 1984). Conjugates synthesized
between this antibody and methotrexate or daunomycin have
been shown to be selectively cytotoxic against an osteogenic
sarcoma cell line (Garnett et al., 1983; Gallego et al., 1984).
Dividing cells have been isolated from primary colorectal
tumours (Durrant et al., 1986b) and their response to free
drug or 791T/36-drug conjugates studied to assess their
potential therapeutic usefulness in this common cancer.
Materials and methods
Clinical specimens
Collection of surgically resected specimens, disaggregation
and in vitro isolation of dividing tumour cell lines has
previously been described (Durrant et al., 1986b).
Cell culture
The basal medium consisted of Dulbecco's minimal essential
medium (DMEM) supplemented with insulin (Sigma, Poole,
Dorset, UK) and pyruvate (Flow Labs., Irving, Fife).
DMEM was enriched with 10% heat inactivated foetal calf
serum and designated IOFDMEM. Newly established cell
lines, C146, C168, C170, 223, 224 and 225 are routinely
passaged twice weekly by detachment with 0.025%
trypsin/EDTA and reseeding in 25cm3 or 75cm3 flasks at
- 106 cells. 277 and 280 are detached by vigorous pipetting
but are seeded at similar densities to the trypsinised lines.
Indirect immunofluorescence
Cells were stained by indirect immunofluorescence as previ-
ously described (Durrant et al., 1984) and analysed on a
FACS IV (Becton Dickinson, Sunnyvale, Ca., USA).
Fluorescein fluorescence was excited at 488 nm and collected
via a 1Onm band with band pass filter centred at 515 nm
after adjustment for standard conditions using fluorochrome-
labelled latex beads. Fluorescence intensity, expressed as
mean linear fluorescence (MLF), was calculated by multi-
plying the contents of each channel by its channel number
and dividing by the total number of cells in the distribution
(Roe et al., 1985). Each cell line was also stained using
normal mouse Ig, and the MLF in this control was sub-
tracted from the values obtained with monoclonal antibody.
The percentage of cells staining was also calculated.
791T/36 monoclonal antibody recognises a glycoprotein of
mol. wt. 72,000 which is found in osteogenic sarcomas, colon
carcinomas and prostate carcinoma (Embleton et al., 1981;
Price et al., 1983).
Cytotoxicity assays
[75Se]-selenomethionine incorporation assay Five thousand
cells were plated in 100y of IOFDMEM in sterilin M29
ART flat bottomed sterile tissue culture microtitre plates and
incubated at 37°C for 2-4h to allow cells to become
adherent. The drug or conjugate at various dilutions was
added in 1OO,I1 of growth medium. Cells were incubated for
64h at 37°C prior to adding 0.1 pl of [75Se]-selenomethionine
in 50pl of growth medium per well. Cells were incubated for
a further 8-16h at 37°C prior to washing gently 3 times with
PBS, drying the plates, spraying with plastic film
(Nobecutane) separating the wells with a band saw and
counting the separate wells in a gamma counter. The
surviving fraction was defined as the number of cpm in wells
containing drug divided by cpm in wells without drug.
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Clonogenic assay One hundred cells were plated in soft agar
(Durrant et al., 1986b) in the presence of various dilutions of
drug or drug antibody conjugates and incubated for 14 days
prior to counting colonies containing 50 or more cells. The
surviving fraction was defined by the number of colonies in
wells containing drugs divided by the number of colonies in
untreated control wells.
Drug-antibody conjugates
Methotrexate was obtained from Lederle Laboratories,
Cyanamid, Gosport, Hants. Conjugates were prepared by an
activated ester method as described previously (Embleton &
Garnett, 1985). Briefly N-hydroxysuccinamide ester of
methotrexate was prepared by the method of Kulkarni et al.
(1981) and reacted with 791T/36 antibody for 1 h. Unreacted
ester and unwanted small molecular weight products were
removed by gel filtration on Sephadex G-25 column. A
conjugate, designated MDC31, had one molecule of 791T/36
antibody substituted with an average of 2.7 molecules of
methotrexate and retained 75% of its binding activity
(Robins et al., 1986). This conjugate was used with cell lines
C146, C168, C170. A similar conjugate, MDC34, containing
1.9 molecules of methotrexate per antibody molecule
retained 84% of its binding activity. This conjugate was used
with cell lines 223, 224, 225, 277 and 280. 14-bromodauno-
mycin was kindly provided by Farmitalia Carlo Erba, Italy.
Conjugates were prepared as described earlier by Gallego et
al. (1984). Briefly, 791T/36 antibody was mixed with a 25
molar excess of 14-bromo-daunomycin dissolved in methanol
for 4h. Following desalting on Sephadex G-25 columns the
excluded fraction containing conjugate was concentrated by
dialysis against Aquacide and centrifuged prior to use. Each
molecule of 791T/36 antibody was substituted with 2-3
molecules of daunomycin and retained 98% of its original
binding activity.
Results
Expression of 791Tp72 antigen on newly established
colorectal cell lines
Eight primary colorectal tumours have successfully been
adapted to in vitro culture. Three of these (C146, C168 and
C170) have previously been characterised in detail (Durrant
et al., 1986b). Table I shows the clinicopathology of these
primary tumours and compares the binding of 791T/36
monoclonal antibody in primary tumours and their in vitro
culture derived cell lines. All the cell lines expressed 791T-
p72 antigen. Furthermore 100% of cells growing in early in
vitro culture (passage 5) express the antigen even when the
primary tumours from which they were isolated had only a
small weakly positive population. 791T/36 monoclonal
antibody bound to the cells with varying intensities ranging
from MLFs 138-454. The level of antigen expression was
relatively stable in the majority of cell lines (Table II).
However, expression in line C146 varied from MLF127-
MLF430 with no obvious correlation with passage number
or growth characteristics.
Sensitivity ofcolorectal cell lines to cytotoxic drugs
All the cell lines were screened by [75Se]-selenomethione
assays for their sensitivity to three cytotoxic drugs, 5-
fluorouracil, methotrexate and daunomycin (Table III).
Table II Stability of expression of 791T-p72 antigen on colorectal
cell lines on prolonged in vitro culture
Binding of 791T/36 monoclonal antibody as assessed by indirect
immunofluorescence (MLF):
Colorectal cell lines
In vitro
passage no. CJ46 C168 C170 223 224 225 277 280
5 377 184 153 443 454 138 278 300
20 127 130 131 480 NDa ND ND 220
50 165 232 180 NAb 398 185 356 460
100 333 225 164 NA 396 187 178 180
150 430 200 200 NA NA NA NA NA
'ND=not done; bNA=not applicable as recently derived cell lines
have not been in continuous culture for sufficient time.
Table Ill Cytotoxicity of 5-fluorouracil, methotrexate and dauno-
mycin to freshly derived colorectal cell lines
Cytotoxicity ofdrugs as measured by [75Se]-selenomethionine
incorporation:
IC50 (nM)
Cell lines 5-fluorouracil Methotrexate Daunomycin
C146 3,800 2,200,000 5,500
C168 3,800 2,200,000 5,500
C170 4,600 2,200,000 550
223 3,800 3,300 185
224 2,300 44 640
225 3,100 18 6
277 230 15 370
280 3,700 29 9
Table I Characteristics of the newly established colorectal cell lines and the tumours
from which they were derived
Binding of791T/36 as assessed
by indirect immunofluorescence:
Clinicopathology
I' tumour cell line
Patient Differ- Tumour
no. entiationa gradeb Site MLFC % + ve MLF % + ve
C146 Adenoma NEe ND 377 97
C168 M D Rectosigmoid 72 ND 184 96
C170 M C Sigmoid 40 ND 153 73
223 M B Ascending 266 47 443 97
224 M B Sigmoid ND ND 454 82
225 W A Sigmoid 179 51 138 89
277 M A Rectum 21 3 278 95
280 P C Hepatic flexure ND ND 300 92
'Tumours were assessed by standard criteria as well (W), moderate (M) or poorly
(P) differentiated; bTumours were graded by Dukes' classfication (Dukes, 1932)
with stage D describing distant metastases; CMLF=Mean linear fluorescence;
d%+ve =The percentage of cells staining with monoclonal antibody 791T/36;
eND=Not done.724 L.G. DURRANT et al.
Seven of the 8 lines had similar sensitivities to 5-fluorouracil
whereas one was ten times more sensitive (Table III). The
cell lines varied in their sensitivities to daunomycin, 225 and
280 were very sensitive whereas C146 and C168 were
resistant to the cytotoxic effects of daunomycin.
There was an enormous difference in sensitivity to metho-
trexate. Three of the lines grew efficiently in 1 mgml - of
methotrexate whereas other lines were killed by doses as
small as 7ngml-'. This resistance was also observed when
C170, C146 and C168 cell lines were assayed by a 14 day
clonogenic assay (data not shown).
Resistance to methotrexate was gradually and irreversibly
lost during continuous culture (Figure 1). Between passages
0-60 all cell lines were 103 times less sensitive to metho-
trexate but by passage 200 C146, C168 and C170 cells were
104-105 times more sensitive to the cytotoxic effects of
methotrexate. However resistance to daunomycin and 5-
fluorouracil remained stable (data not shown).
Sensitivity ofcolorectal cells to 791T/36-drug conjugates
The instability of the cell lines as regards methotrexate
sensitivity was not anticipated but as soon as it was observed
(passage 50) the cell lines were screened for the sensitivity to
791T/36 conjugated to methotrexate. The C170, C146, C168
cells at this passage were still 103 fold more reistant than
the other cell lines and 103 fold more resistant than they
eventually became on further in vitro culturing. Furthermore
the loss of resistance was irreversible, as growing cells
following exposure to mutagens, in methotrexate failed to
reverse the trend (unpublished data). C146, C168, C170 cell
lines were more sensitive to the conjugated methotrexate
than to the free drug at passage 50-53 (Figure 2). However
as they continued to lose their resistance to free drug their
sensitivity to conjugate remained unaltered (Table IV). Cell
lines which were very sensitive to free drug at early passages
were less sensitive to 791T/36-methotrexate (Table IV). C170
cells were injected into nude mice at in vitro passage number
40 (Durrant et al., 1986b). Following 10 in vivo transplan-
tations cells were reintroduced to in vitro culture and
immediately assayed for methotrexate and 791T/36 metho-
trexate sensitivity. These cells had identical sensitivities to
cells maintained in vitro culture for 50 passages and were
C146
Table IV Sensitivity of a series of colorectal cell lines to 791T/36
drug conjugates and free drug
Cytotoxicity ofdrug or conjugates as measured by
[[75Se]-selenomethionine incorporation:
IC50 ±s.e. (nM)a
791T/36-
Cell lines Methotrexate Methotrexate
in vitro passage 5-8
225 20+7 432+85b
277 15+2 447+84
280 26+2 702+126b
in vitro passage 50-53
C146 2,140+145 112+24b
C168 11,407+2,570 786+93C
C170 3,940+370 357+57b
223 46+4 363+62C
224 46+4 436+88C
in vitro passage 200-203
C168 18+4 619+90b
C170 8+2 888+ 112b
Cell lines Daunomycin 791T/36-Daunomycin
in vitro passage 50-
C168 5,500 5 Wod
C170 550 500d
aIC50 +s.e. are from 3 separate experiments performed at
consecutive passages; bp<0.001 when comparing cytotoxicity of free
drug to conjugated drug; CP<0.01 when comparing cytotoxicity of
free drug to conjugated drug; dNot significant when comparing
cytotoxicity of free drug to conjugated drug.
more sensitive to conjugate than free methotrexate (Figure
3). Only two lines (C168 and C170) were screened with the
daunomycin-791T/36 conjugate as it was in limited supply.
Both lines had similar sensitivities to free or conjugated
daunomycin although one line, C168 was 10 times more
resistant than C170 (Figure 4).
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Figure 1 Loss of resistance of colorectal cell lines C146, C168 and C170 to methotrexate on prolonged in vitro culture. (0)
passages 30-40. (A) passages 46-50. (M) passages 60-64. If error bars are not shown it is because they are encompassed by the
symbol.
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Figure 2 In vitro cytotoxicity of free methotrexate (A) and 791T 36 methotrexate conjugate (0) to colorectal tumour cell lines
C146. C168 and C170 at passages 50-53.
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Figure 4 In vitro cytotoxicity of free daunomycin (0) and
791T 36 daunomycin (0) to colorectal tumour cell lines. C170
and C168.
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Figure 3 In vitro cytotoxicity of free methotrexate (A) and
791T 36 methotrexate (0) to colorectal tumour cell line C170 at
passage 50. In vitro cytotoxicity of free methotrexate (A) and
791T 36 methotrexate (0) to C170 cells injected into nude miice
at passage 40 and grown as xenografts for 10 passages pnror to
reintroduction into culture.
Discussion
Two major problems are associated with chemotherapy of
human tumours. vi-., drug resistance and the toxic side
effects of drugs on normal cells. Previous studies have shown
that 791T,36 monoclonal antibody localises in the tumours
of patients with colorectal cancer (Farrands et al., 1983;
Armitage et al., 1984). It can therefore act as a potential
carrier of drugs to tumour cells and reduce normal drug
toxicity. This monoclonal antibody also binds to the cell
surface of colorectal tumour cells (Durrant et al., 1986) and
may therefore act as a transplasma membrane carrier of
cytotoxic drugs (Garnett & Baldwin, 1986; Shen et al., 1986).
This hypothesis has been tested by screening 791T/36 drug
conjugates on eight new colorectal cell lines with varying
sensitivities to cytotoxic drugs.
Daunomycin was the most cytotoxic drug in cell lines
C170, 223, 225 and 280, methotrexate was the most effective
drug in cell lines 224 and 277 whereas 5-fluorouracil was the
most cytotoxic drug in only 2 cell lines, C168 and C146.
Both of these cell lines were resistant to methotrexate and
daunomycin. Although 5-fluorouracil is at present the drug
of choice for chemotherapy of colorectal cancer, the overall
clinical response rate to this drug is less than 25% and its
use has not significantly improved the survival of patients
with large bowel cancer (Davis, 1982; Gilbert, 1982). Only
25% of the cell lines used in this study were more sensitive
to 5-fluorouracil than methotrexate or daunomycin. They
also had similar sensitivities to 5-fluorouracil as other
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colorectal lines developed in other laboratories (Dexter et al.,
1981; Kimball & Brittain, 1980). These results suggest that
daunomycin may be a better choice of drug for
chemotherapy of colorectal cancer.
Half of the cell lines were resistant to the cytotoxic effect
of methotrexate. However, these lines were rendered sensitive
to this drug when it was attached to 791T/36. In fact, all of
the cell lines had a similar sensitivity to 791T/36-metho-
trexate despite their varying sensitivities to free drug. This
supports the concept that monoclonal antibody methotrexate
conjugates enter the cell by a separate mechanism to the
normal active transport system for methotrexate uptake
(Shen et al., 1986). As one of the major causes of metho-
trexate resistance is defective drug transport (Curt et al.,
1984), monoclonal antibody methotrexate conjugates should
be much more effective in therapy of either naturally or
acquired drug resistant tumours.
Two of the cell lines which were resistant to daunomycin
were treated with a 791T/36-daunomycin conjugate. How-
ever, unlike their response to 791T/36-methotrexate, they
were as resistant to 791T/36-daunomycin as to free drug.
Increased active transport of daunomycin out of cells has
resulted in resistance to this drug (Dano, 1973). Whether free
drug was taken up by diffusion, or conjugated drug internal-
ised as a monoclonal antibody conjugate, enhanced extra-
cellular transport would result in similar resistance to free
drug or monoclonal antibody drug conjugate.
The methotrexate resistant cell lines became increasingly
sensitive to this drug in in vitro culture. However, expression
of 791T p72 antigen, sensitivities to 5-fluorouracil and
daunomycin, and their ability to grow as xenografts in nude
mice remained unaltered. Similarly if the cell lines were
passaged as xenotransplants in nude mice they still lost their
methotrexate resistant at a similar rate to cells in in vitro
culture. It must therefore be assumed that the environment
of the human colon favours the growth of methotrexate
resistant tumours, whereas in vitro culture or xenotransplan-
tation in the flanks of nude mice favours the growth of
methotrexate sensitive tumour cells.
Monoclonal antibody drug conjugates may not only
reduce toxic side effects of drugs on normal cells but offer an
alternative intracellular transport mechanism for cytotoxic
drugs.
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